Pharmacological inhibition of eIF3B enhances PD‐1/PD‐L1 blockade sensitivity by boosting MHC‐I levels, offering a new therapeutic approach for NSCLC patients with high miR‐23a/27a/24‐2 expression.57 Here, EIF3B is linked to non-small cell lung carcinoma.